Friday, 16 October 2026European Markets

BAM GROEP KON Stock Bullish By 11% At Session Start Today

Loading stream...

(VIANEWS) - Shares of BAM GROEP KON (AEX-Index: BAMNB.AS) rose by a staggering 11.51% to €2.83 at 10:09 EST on Thursday, following the last session's upward trend. AEX-Index is jumping 0.55% to €773.96, after three successive sessions in a row of gains. This seems, up until now, a somewhat positive trend exchanging session today.

BAM GROEP KON's last close was €2.53, 24.18% below its 52-week high of €3.33.

About BAM GROEP KON

Koninklijke BAM Groep nv, together with its subsidiaries, provides products and services in the construction and property, civil engineering, and public private partnerships (PPP) sectors worldwide. The company designs, develops, constructs, and maintains public, residential and non-residential, infrastructure, turn-key construction, and civil architecture and industrial construction projects; and provides project development, design, and engineering services, as well as rail infrastructure, facilities management, volumetric modular housing, and property development services. It also undertakes various civil and marine engineering projects; and operates PPP in road, rail, education, health care, judicial, and general projects. Koninklijke BAM Groep nv was founded in 1869 and is headquartered in Bunnik, the Netherlands.

Earnings Per Share

As for profitability, BAM GROEP KON has a trailing twelve months EPS of €-0.452.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 11.76%.

More news about BAM GROEP KON (BAMNB.AS).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com